SCHEMBL30730596

SCHEMBL30730596

Cc1nonc1CC(=O)N1CCC(n2nnc(-c3ccc(C(F)(F)F)cc3)n2)CC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.42
LMNA P02545 4/20 0.41
ALDH1A1 P00352 2/20 0.41
PKM P14618 2/20 0.41
HDAC4 P56524 3/20 0.41
HDAC6 Q9UBN7 2/20 0.41
KCNJ6 P48051 1/20 0.41
KCNJ5 P48544 1/20 0.41
KCNJ3 P48549 1/20 0.41
GAA P10253 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPT P10636 1/20 0.38
GFER P55789 1/20 0.38
RAB9A P51151 1/20 0.38
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30730585 0.90 LMNA (0.47) LMNAALDH1A1PKMKCNJ6KCNJ5
SCHEMBL30730663 0.90 PKM (0.44) LMNAALDH1A1PKMGAASMN1; SMN2
SCHEMBL30730618 0.88 PKM (0.54) ENPP2LMNAALDH1A1PKMHTT
SCHEMBL32676970 0.88 RAB9A (0.50) LMNAALDH1A1PKMMAPTGFER
SCHEMBL30730540 0.87 PKM (0.44) LMNAALDH1A1PKMHDAC4HDAC6
SCHEMBL30730615 0.83 GRM5 (0.43) ALDH1A1PKMKCNJ6KCNJ5KCNJ3
SCHEMBL30730676 0.83 LMNA (0.60) LMNAGAAHTTSMN1; SMN2MAPT
SCHEMBL30730693 0.81 PKM (0.45) ENPP2LMNAALDH1A1PKMGFER
SCHEMBL30730647 0.81 RAB9A (0.46) LMNAALDH1A1PKMKCNJ6KCNJ5
SCHEMBL30730669 0.79 LMNA (0.41) LMNAALDH1A1PKMHDAC4HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US claimed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO claimed
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US disclosed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE FNTB, PDE7A, TBL3 ENPP2 591/4885LMNA 1838/4885ALDH1A1 2154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.